K. Shinomiya

K. Katsumata1
H. Hagino1
1K. Katsumata
1H. Hagino
Learn More
UNLABELLED The MOVEST study evaluated the efficacy and safety of monthly oral ibandronate versus licensed monthly IV ibandronate in Japanese osteoporotic patients. Relative BMD gains after 12 months were 5.22 % oral and 5.34 % IV, showing non-inferiority of oral to IV ibandronate (primary endpoint). No new safety concerns were identified. INTRODUCTION The(More)
  • 1